RPRX — Royalty Pharma plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1802768 ·
Last close
$55.35
Market Cap
$24.54B
52W High
$56.50
52W Low
$44.95
ADV30
4,226,658
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 630,576,000 | — | 632,481,000 | 294,690,000 | 19,815,415,000 | 586,395,000 | 9,878,582,000 |
| Dec 2025 | 621,990,000 | — | 388,382,000 | 214,205,000 | 19,620,780,000 | 618,696,000 | 9,905,841,000 |
| Sep 2025 | 609,291,000 | — | 427,156,000 | 288,217,000 | 19,347,280,000 | 938,944,000 | 9,726,419,000 |
| Jun 2025 | 578,665,000 | — | 209,799,000 | 30,176,000 | 18,323,000,000 | 631,908,000 | 8,820,060,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$2,611,980,000
Investing CF
$-2,595,962,000
Financing CF
$-517,343,000
CapEx
—
Dividends Paid
$-387,386,000
Buybacks
$-568,702,000
EPS Diluted TTM
$1.65
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$2,507,091,000
Inventory
—
Receivables
$27,511,000
ST Investments
$801,744,000
EBIT TTM
$1,695,140,000
Pretax Income TTM
$1,359,015,000
Interest Exp TTM
$336,125,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,440,521,984
EBITDA
—
Free Cash Flow
$-980,302,528
Enterprise Value
$35,950,149,632
Total Cash
$608,294,976
Total Debt
$8,974,935,040
Shares Out
443,274,104
Trailing EPS
$1.90
Book Value
$15.53
ROE
13.8%
ROA
5.5%
Div Yield
1.70%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,378,193,000 | 1,559,518,000 | 770,947,000 | 19,620,780,000 | 9,905,841,000 | — | 2,489,823,000 |
| Dec 2024 | 2,263,576,000 | 1,292,444,000 | 858,983,000 | 18,222,715,000 | 7,880,349,000 | — | 2,768,986,000 |
| Dec 2023 | 2,354,554,000 | 1,492,150,000 | 1,134,834,000 | 16,381,851,000 | 6,297,562,000 | — | 2,987,802,000 |
| Dec 2022 | 2,237,215,000 | 922,892,000 | 42,832,000 | 16,813,466,000 | 7,288,093,000 | — | 2,143,980,000 |
TTM Snapshot
Revenues TTM
$2,260,239,000
NetIncome TTM
$860,681,000
OpCashFlow TTM
$0
Assets (Latest)
$18,222,715,000
Forward EPS
$5.61
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ROIV | Roivant Sciences Ltd. | $23.17B | $32.21 | — |
| UTHR | UNITED THERAPEUTICS Corp | $23.11B | $544.33 | — |
| ONC | BeOne Medicines Ltd. | $26.20B | $276.13 | — |
| BEIGF | BeOne Medicines Ltd. | $27.08B | $21.95 | — |
| INSM | INSMED Inc | $22.14B | $102.15 | — |
News headlines (Yahoo Finance, 1h cache)
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)
2026-06-15 16:28 · Yahoo
This Royalty Pharma Insider Reduced Their Stake By 10%
2026-06-12 14:00 · Yahoo
3 Unpopular Stocks We’re Skeptical Of
2026-06-12 12:13 · Yahoo
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?
2026-06-10 15:30 · Yahoo
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings?
2026-06-09 14:06 · Yahoo
Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
2026-06-04 20:15 · Yahoo
Mattel Stock Is Down 24%. Here's What a $50.9 Million Exit Could Mean
2026-05-30 00:34 · Yahoo
Royalty Pharma (RPRX) Valuation Check After Strong Share Price Momentum And Royalty Growth Potential
2026-05-25 23:11 · Yahoo
3 Mid-Cap Stocks We Steer Clear Of
2026-05-20 10:04 · Yahoo
Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance
2026-05-18 12:32 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.